ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy
ENCell has entered into a strategic alliance and licencing agreement with Lucy Biotech for EN001, a next-generation mesenchymal stem cell therapy.
ENCell has entered into a strategic alliance and licencing agreement with Lucy Biotech for EN001, a next-generation mesenchymal stem cell therapy.
German company Merck has introduced the first single-use reactor specifically designed for the production of antibody-drug conjugates (ADCs).
Novartis has announced the commencement of construction on two new radioligand therapy (RLT) manufacturing facilities in the US, in a bid to expand its production and supply chain capabilities in the sector.
RedHill Biopharma has launched Talicia in the UAE, a treatment option for adults with Helicobacter pylori (H. pylori) infection.
Merck has initiated commercial manufacturing of its first Good Manufacturing Practices (GMP)-compliant manufacturing line for cell culture media (CCM) in China.
Rosemont Pharmaceuticals, a developer of liquid medicines, has announced the acquisition of Pharma-Data, a research and development organisation based in Lavrion, Greece, enhancing its ability to develop products for worldwide market.
Amneal Pharmaceuticals has initiated the distribution of its over-the-counter (OTC) Naloxone Hydrochloride (Naloxone HCI) Nasal Spray, USP, 4mg, to retail pharmacies across the US, including the State of California.
Sol-Gel Technologies has entered into an asset purchase agreement with Shenzhen Beimei Pharmaceutical, granting the latter exclusive rights to commercialise Sol-Gel’s dermatology product TWYNEO in mainland China, Taiwan, Hong Kong, Macau, and Israel.
Scorpius Holdings, an integrated contract development and manufacturing organisation (CDMO), has confirmed the successful current Good Manufacturing Practice (cGMP) facility validation for microbial manufacturing.
PharmaLogic, a contract development and manufacturing organization (CDMO) and provider of radiopharmacy solutions, has announced the launch of its new radiopharmaceutical manufacturing and research facility at the Bronx in New York city, US.